Vermillion Inc (VRML)
Vermillion is engaged in discovering, developing and commercializing diagnostic and bio-analytical solutions that assist physicians diagnose, treat and improve outcomes for women. Co.'s tests are to detect, characterize and stage disease, and to assist guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy. Co. focuses its development of diagnostic tests for gynecologic disease, with an initial focus on ovarian cancer. Co.'s main product, OVA1, is a blood test designed to identify women who are at high risk of having a malignant ovarian tumor prior to surgery.